Skip to content
Peptide.Guide

FDA Category 2 · restricted from compounding

This compound is on the FDA’s interim Section 503A Category 2 bulks list and cannot be legally compounded by US pharmacies. An HHS announcement in February 2026 signaled intent to restore several peptides to Category 1, but no Federal Register action has been published. Check the FDA PCAC schedule for updates.

Read the full regulatory context
PreclinicalGrowth HormoneSubQ1–3x per day

CJC-1295 + Ipamorelin

CJC/Ipa · GHRH + GHRP combo

Classic GHRH + GHRP combination that amplifies endogenous GH pulses more than either alone.

Read dosing protocol

§ 01   Overview

Overview

Classic GHRH + GHRP combination that amplifies endogenous GH pulses more than either alone.

Widely used in research / compounding; no late-stage FDA outcome trials.

§ 02   Mechanism

Mechanism of action

Combines the short-acting GHRH analog CJC-1295 (no DAC) with the selective ghrelin receptor agonist Ipamorelin. The two act on different pituitary receptors and produce a larger GH pulse than either alone.

  • 01Larger physiological GH pulses
  • 02Improved recovery and sleep anecdotally
  • 03Clean side-effect profile of Ipamorelin preserved

§ 03   Dosing

Dosing protocol

Standard Protocol

Vial
5 mg / 5 mg combo vial
BAC Water
2 ml BAC water
Dose Range
100 – 300 mcg of each peptide
Starting Dose
100 mcg CJC + 100 mcg Ipamorelin
Route
SubQ
Timing
Before bed or pre-workout, empty stomach
Frequency
1–3x per day
Cycle
8–12 weeks on, 4 off

§ 04   Evidence

Evidence & research

Preclinical

Widely used in research / compounding; no late-stage FDA outcome trials.

FDA Status

Not FDA-approved.

§ 05   Stacks

Common stacks

CJC-1295 (No DAC)

Individual components

Ipamorelin

Individual components

§ 06   News

In the news

5 articles from the last 12 months · updates hourly

§ 07   Sourcing

Sourcing & supply

Regulatory status

Restricted from compounding

Placed on the FDA's 503A Category 2 list and cannot be lawfully compounded in the US. No brand pharmacy alternative exists. US buyers encounter only research-use-only (RUO) channels, which the FDA's Intended Use Doctrine treats as unapproved drug sales.

Telehealth (Rx) · 3

Telehealth

Defy Medical

Rx required

Broadest peptide formulary in legitimate US telehealth. 13-year history, concierge cash-pay, no known lawsuits.

Visit
Telehealth

Marek Health

Rx required

Premium hormone optimization. All 50 states. 4.8 Trustpilot. Partners include Hallandale.

Visit
Telehealth

Blokes / Joi Women's Wellness

Rx required

Men's + women's optimization platform. TRT in 34 states. 4.6–4.8 Trustpilot.

Visit

Listings are informational, not endorsement. Verify credentials and flags against FDA and PCAB databases before purchasing. Full directory & how to verify →

§ 09   Safety

Safety & side effects

Side effects

  • 01Flushing, mild water retention

Contraindications

None specified.

◆   In this categoryMore from Growth Hormone
01

Ipamorelin

Selective ghrelin receptor agonist that releases GH without meaningfully raising cortisol or prolactin. The cleanest GHRP.

Preclinical
02

CJC-1295 (No DAC)

Short-acting GHRH analog that amplifies natural GH pulses. Almost always paired with a GHRP like Ipamorelin.

Preclinical
03

Tesamorelin

FDA-approved GHRH analog that specifically reduces visceral adipose tissue (VAT), originally developed for HIV-associated lipodystrophy.

Established
04

AOD-9604

C-terminal fragment of human growth hormone marketed for lipolytic effects without the IGF-1 or insulin resistance effects of full-length GH.

Experimental
05

AOD-9604 (Capsule)

Oral capsule form of AOD-9604 with limited bioavailability compared to injectable form.

Experimental

This site is for educational and research purposes only. It does not constitute medical advice. Always consult a qualified healthcare provider before using any peptide or supplement.